08:30 AM EDT, 10/10/2025 (MT Newswires) -- Biogen (BIIB) and Stoke Therapeutics ( STOK ) on Thursday presented new data which they said support the potential of zorevunersen as a disease-modifying medicine for Dravet syndrome.

A two-year analysis related to the phase 3 dosing plan showed "continuing improvements in cognition and behavior," versus minimal change in a two-year natural-history group on standard care, the company said.

Clinicians and caregivers also reported better overall clinical status for 95% of treated patients over three years, Biogen said.

Shares of Stoke Therapeutics ( STOK ) were up 1.4% in recent premarket trading, while Biogen was up 0.3%.